AR055070A1 - Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso - Google Patents

Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso

Info

Publication number
AR055070A1
AR055070A1 ARP060102820A ARP060102820A AR055070A1 AR 055070 A1 AR055070 A1 AR 055070A1 AR P060102820 A ARP060102820 A AR P060102820A AR P060102820 A ARP060102820 A AR P060102820A AR 055070 A1 AR055070 A1 AR 055070A1
Authority
AR
Argentina
Prior art keywords
composition
pharmaceutical composition
preparation
same
active agent
Prior art date
Application number
ARP060102820A
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Sukhjeet Singh
Sanjay Boldhane
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR055070A1 publication Critical patent/AR055070A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Composicion farmacéutica de liberacion sostenida que comprende por lo menos un agente activo o sus formas tautoméricas, análogos, isomeros, polimorfos, solvatos o sales de los mismos; preferiblemente se provee un agente activo antiviral. También se provee un proceso de preparacion de tal composicion y método para su utilizacion. Las composiciones de liberacion sostenida de la presente pueden suministrar el agente activo de manera deseada durante un período prolongado. Uso. Reivindicacion 2: Una composicion tal como se reivindica en (1), caracterizada porque el agente activo se selecciona de un grupo que comprende un agente antiviral, cimetidina, ranitidina, captopril, metformina, bupropion, fexofenadina, oxcarbacepina, levetiracetam, tramadol o sus formas tautoméricas, análogos, isomeros, polimorfos, solvatos, derivados o sales de los mismos utilizados solos o en combinacion.
ARP060102820A 2005-06-29 2006-06-29 Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso AR055070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1680DE2005 2005-06-29

Publications (1)

Publication Number Publication Date
AR055070A1 true AR055070A1 (es) 2007-08-01

Family

ID=37027780

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102820A AR055070A1 (es) 2005-06-29 2006-06-29 Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso

Country Status (15)

Country Link
US (1) US20090099154A1 (es)
EP (1) EP1912628A2 (es)
JP (1) JP2009500318A (es)
CN (1) CN101212957A (es)
AR (1) AR055070A1 (es)
AU (1) AU2006263338A1 (es)
BR (1) BRPI0613070A2 (es)
CA (1) CA2613407A1 (es)
CR (1) CR9705A (es)
EA (1) EA200800162A1 (es)
MX (1) MX2008000084A (es)
NO (1) NO20080399L (es)
RS (1) RS20070512A (es)
TN (1) TNSN07490A1 (es)
WO (1) WO2007000779A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018160B1 (en) 2006-03-16 2011-12-14 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
MX2008015571A (es) * 2006-06-08 2009-04-24 Univ Yale Metodo de destilado de columna de etapa multiple (mscd) para recuperacion de una sustancia disuelta osmotica.
JP5547966B2 (ja) * 2006-12-15 2014-07-16 カンピナ ネーデルランド ホールディング ビー．ブイ． 持続放出用の賦形剤及びその使用
EP1935411A1 (en) * 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
WO2008090569A1 (en) * 2007-01-25 2008-07-31 Panacea Biotec Ltd Modified release pharmaceutical composition and a process of making the same
KR101017862B1 (ko) 2007-06-08 2011-03-04 베링거 인겔하임 인터내셔날 게엠베하 네비라핀의 서방성 제형
ES2406939T3 (es) * 2007-10-19 2013-06-10 Otsuka Pharmaceutical Co., Ltd. Preparación farmacéutica de matriz sólida
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
BR112012019374B1 (pt) * 2010-02-03 2022-01-11 Pharma Two B Ltd Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas
WO2011117875A1 (en) * 2010-03-26 2011-09-29 Hetero Research Foundation Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium
KR20120055313A (ko) * 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
CN102058553B (zh) * 2010-12-28 2012-10-10 哈药集团三精制药股份有限公司 阿昔洛韦缓释片及其制备方法
JP5976657B2 (ja) 2011-09-30 2016-08-24 持田製薬株式会社 易服用性固形製剤
FR2983409B1 (fr) * 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法
RU2605279C2 (ru) 2012-03-21 2016-12-20 Космедерм Байосайенс, Инк. Применяемые местно стронцийсодержащие комплексы для лечения боли, зуда и воспаления
EP2995299B1 (en) * 2013-05-08 2021-04-07 Zensei Pharmaceutical Industries Co., Ltd. Functional polymer film-coated particle having high drug content, tablet containing same, and methods for production thereof
US20160193182A1 (en) * 2013-08-14 2016-07-07 Evonik Roehm Gmbh Coating composition
US20160250253A1 (en) * 2013-09-24 2016-09-01 Cosmederm Bioscience, Inc. Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus
CN103705933A (zh) * 2013-12-18 2014-04-09 北京科源创欣科技有限公司 奥卡西平药物组合物及制备方法
JP6532765B2 (ja) * 2014-06-06 2019-06-19 株式会社ファンケル 即効性成分と持続性成分を含む錠剤
BR112017011198A2 (pt) 2014-11-26 2018-06-26 Evonik Röhm Gmbh composição farmacêutica ou nutracêutica com resistência contra a influência do etanol.
CN104666267B (zh) * 2015-03-27 2017-08-08 康普药业股份有限公司 一种阿昔洛韦药物组合物
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
CN106943356B (zh) * 2017-05-10 2019-11-08 武汉人福药业有限责任公司 一种泛昔洛韦缓释颗粒剂及其制备方法
JP6958856B2 (ja) * 2017-08-09 2021-11-02 日本臓器製薬株式会社 錠剤
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN109466152B (zh) * 2018-09-04 2021-01-26 浙江罗奇泰克科技股份有限公司 一种高导热铁基板的制作方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE133068T1 (de) * 1991-01-30 1996-02-15 Wellcome Found Wasserlösliche tabletten
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US20030134864A1 (en) * 1996-02-07 2003-07-17 Smithkline Beecham P.L.C. Activity of penciclovir against epstein-barr virus
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
SK285478B6 (sk) * 1998-09-14 2007-02-01 Ranbaxy Laboratories Limited Jednodenná formulácia na orálne podanie na kontrolované uvoľňovanie ciprofloxacínu
WO2002102415A1 (en) * 2001-06-18 2002-12-27 Blue Cross Laboratories Limited Gastric floating system
EP1530458A1 (en) * 2002-08-14 2005-05-18 Ranbaxy Laboratories, Ltd. Extended release matrix tablets
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery

Also Published As

Publication number Publication date
TNSN07490A1 (en) 2009-03-17
AU2006263338A1 (en) 2007-01-04
EA200800162A1 (ru) 2008-06-30
AU2006263338A2 (en) 2008-06-05
EP1912628A2 (en) 2008-04-23
CN101212957A (zh) 2008-07-02
WO2007000779A3 (en) 2007-06-28
MX2008000084A (es) 2008-03-18
CA2613407A1 (en) 2007-01-04
US20090099154A1 (en) 2009-04-16
BRPI0613070A2 (pt) 2010-12-21
WO2007000779A2 (en) 2007-01-04
NO20080399L (no) 2008-03-31
RS20070512A (en) 2009-01-22
CR9705A (es) 2008-10-30
JP2009500318A (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
AR055070A1 (es) Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso
UY27516A1 (es) Bencimidazoles
CR7069A (es) Derivados de pirazol para el tratamiento de vih
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
GT200100132A (es) Derivados de pirazol
HN2003000417A (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
UY28510A1 (es) Compuestos quimicos
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
CL2009001059A1 (es) Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
DOP2006000243A (es) Derivados de pirazina
PA8577101A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY28800A1 (es) 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparación y el uso de las mismas para combatir hongos nocivos
CR8278A (es) Combinaciones sinergicas de productos activos, fungicidas
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
GT200500309A (es) Derivados de sulfonilbencilimidazol
GT200900001A (es) Composicion farmaceutica que contiene un acido tetra hidrofolico
ECSP088296A (es) Compuestos terapéuticos
PA8623101A1 (es) Compuestos farmaceuticamente activos
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
UY30736A1 (es) Compuestos quimicos 537
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal